This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Osmolarity, Dry Eye Disease And TearLab, Front And Center At ARVO 2010

SAN DIEGO, May 6, 2010 (GLOBE NEWSWIRE) -- OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB) today announced today that a variety of paper and poster presentations given at the 2010 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) highlighted tear film osmolarity as the preferred tool in the evaluation of patients suffering from Dry Eye Disease ("DED") and further validated TearLab's™ unique ability to accurately measure subtle changes in the condition of the ocular surface.

ARVO was founded in 1928 and is the largest research gathering for ophthalmologists and vision scientists in the world. Its membership is comprised of more than 12,500 individuals from 70 countries. The membership is multidisciplinary and consists of both clinical and basic researchers. ARVO is based in Rockville, Maryland.  This year's ARVO annual meeting was held in Fort Lauderdale, Florida.

One poster presentation, entitled "Longitudinal Variability of Tear Film Osmolarity in Normal and Dry Eye Patients" and presented by David Eldridge, OD, FAAO, described a study that was designed to evaluate the variability of right ("OD") and left ("OS") eye tear film osmolarity relative to tear film instability in the diagnosis of DED. At each subject visit, 50 nanoliters of tear fluid was simultaneously collected and analyzed (both OD and OS) by the TearLab™ Osmolarity System in triplicate. The average of normal subjects was 301.8±10.5 mOsms/L {range 290.2-307.7} while the average of hyperosmolar subjects was 315.6±18.6 mOsms/L {range 308.1-329.4} indicating early stage mild disease. Variability was strongly positively correlated with average osmolarity (r2 = 0.52), suggesting that tear film instability increased in DED.  When the highest of either the OD or OS osmolarity result of an individual was considered, 86% of the early stage, mild dry eye subjects, the most difficult stage to diagnose, were correctly identified with the first set of measurements. Dr. Eldridge's presentation concluded that variability in osmolarity is a hallmark of DED, reflecting the inability of the patient to maintain tear film homeostasis. Therefore, he recommended that physicians test both eyes to diagnose DED and use the higher of two values for proper clinical assessment.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
TLB $0.00 0.00%
TEAR $2.33 0.00%
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs